<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> OPKO Health, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	November 5, 2015
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	OPKO Health, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33528
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	75-2402409
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	4400 Biscayne Blvd., Miami, Florida
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	33137
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(305) 575-4100
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END -->



<P align="left" style="font-size: 10pt"><FONT style="font-size: 10pt"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement.</B>
</FONT>

<P align="left" style="font-size: 10pt; text-indent: 1%">On November&nbsp;5, 2015, a wholly-owned subsidiary of OPKO Health, Inc. (the &#147;Company&#148;),
Bio-Reference Laboratories, Inc. (&#147;BRLI&#148;), and certain of its subsidiaries entered into a new
credit agreement with JPMorgan Chase Bank, N.A. (&#147;CB&#148;), as lender and administrative agent (the
&#147;New Credit Agreement&#148;), which replaces BRLI&#146;s existing loan agreement with PNC Bank, National
Association (the &#147;Existing Loan Agreement&#148;). The New Credit Agreement provides for a $175.0
million secured revolving credit facility and includes a $20.0&nbsp;million sub-facility for swingline
loans and a $20.0&nbsp;million sub-facility for the issuance of letters of credit. BRLI may increase
the credit facility to up to $275.0&nbsp;million on a secured basis, subject to the satisfaction of
specified conditions. The new credit facility matures on November&nbsp;5, 2020 and is guaranteed by all
of BRLI&#146;s domestic subsidiaries. The new credit facility is also secured by substantially all
assets of BRLI and its domestic subsidiaries, as well as a non-recourse pledge by the Company of
its equity interest in BRLI. Availability under the New Credit Agreement is based on a borrowing
base comprised of eligible accounts receivables of BRLI and certain of its subsidiaries, as
specified therein. The proceeds of the new credit facility will be used to refinance existing
indebtedness, including amounts outstanding under the Existing Loan Agreement which has been
terminated in accordance with its terms, to finance working capital needs and for general corporate
purposes of BRLI and its subsidiaries.


<P align="left" style="font-size: 10pt; text-indent: 1%">At BRLI&#146;s option, borrowings under the New Credit Agreement (other than swingline loans) will
bear interest at (i)&nbsp;the CB floating rate (defined as the higher of (a)&nbsp;the prime rate and (b)&nbsp;the
LIBOR rate (adjusted for statutory reserve requirements for eurocurrency liabilities) for an
interest period of one month plus 2.50%) plus an applicable margin of 0.35% for the first 12&nbsp;months
and 0.50% thereafter or (ii)&nbsp;the LIBOR rate (adjusted for statutory reserve requirements for
eurocurrency liabilities) plus an applicable margin of 1.35% for the first 12&nbsp;months and 1.50%
thereafter. Swingline loans will bear interest at the CB floating rate plus the applicable margin.
The New Credit Agreement also calls for other customary fees and charges, including an unused
commitment fee of 0.25% of the lending commitments.


<P align="left" style="font-size: 10pt; text-indent: 1%">The New Credit Agreement contains customary covenants and restrictions, including, without
limitation, covenants that require BRLI and its subsidiaries to maintain a minimum fixed charge
coverage ratio if availability under the new credit facility falls below a specified amount and to
comply with laws, and restrictions on the ability of BRLI and its subsidiaries to incur additional
indebtedness or to pay dividends and make certain other distributions to the Company, subject to
certain exceptions as specified therein. Failure to comply with these covenants would constitute
an event of default under the New Credit Agreement, notwithstanding the ability of BRLI to meet its
debt service obligations. The New Credit Agreement also includes various customary remedies for
the lenders following an event of default, including the acceleration of repayment of outstanding
amounts under the New Credit Agreement and execution upon the collateral securing obligations under
the New Credit Agreement.


<P align="left" style="font-size: 10pt; text-indent: 1%">The foregoing description of the New Credit Agreement is only a summary and is qualified in
its entirety by reference to the full text of the New Credit Agreement.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;1.02. Termination of a Material Definitive Agreement.</B>


<P align="left" style="font-size: 10pt; text-indent: 1%">The information set forth under Item&nbsp;1.01 of this Current Report on Form 8-K regarding the
termination of the Existing Loan Agreement is incorporated by reference into this Item&nbsp;1.02.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><B>Item&nbsp;2.03.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement of a Registrant.</B></TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt; text-indent: 1%">The information set forth under Item&nbsp;1.01 of this Current Report on Form 8-K regarding the New
Credit Agreement is incorporated by reference into this Item&nbsp;2.03.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><B>Item&nbsp;7.01.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Regulation&nbsp;FD Disclosure.</B></TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt; text-indent: 1%">On November&nbsp;6, 2015, the Company issued a press release announcing that it entered into the
New Credit Agreement. A copy of the press release is being filed as Exhibit&nbsp;99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.


<P align="left" style="font-size: 10pt; text-indent: 1%">The information contained in Item&nbsp;7.01 to this Current Report on Form 8-K and Exhibit&nbsp;99.1
attached hereto shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Exchange Act, or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing by the Company under the Exchange Act.



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->

<!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	OPKO Health, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	November 6, 2015
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Adam Logal
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Adam Logal
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Senior Vice President-Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press Release of the Company, dated November 6, 2015
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
[{"type": "8-K", "sequence": "1", "filename": "htm_52685.htm", "description": "LIVE FILING", "secsgml_size_bytes": 15437}]
{"company-data": {"conformed-name": "Opko Health, Inc.", "cik": "0000944809", "assigned-sic": "2834", "irs-number": "752402409", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33528", "film-number": "151213096"}, "business-address": {"street1": "4400 BISCAYNE BLVD.", "city": "MIAMI", "state": "FL", "zip": "33137", "phone": "305-575-4138"}, "mail-address": {"street1": "4400 BISCAYNE BLVD.", "city": "MIAMI", "state": "FL", "zip": "33137"}, "former-company": [{"former-conformed-name": "eXegenics Inc", "date-changed": "20040505"}, {"former-conformed-name": "EXEGENICS INC", "date-changed": "20011114"}, {"former-conformed-name": "CYTOCLONAL PHARMACEUTICS INC /DE", "date-changed": "19950503"}]}
OPKO Health, Inc. (Form: 8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 5, 2015
OPKO Health, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware
001-33528
75-2402409
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
4400 Biscayne Blvd., Miami, Florida
33137
_________________________________
(Address of principal executive offices)
___________
(Zip Code)
Registrant's telephone number, including area code:
(305) 575-4100
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 1.01. Entry into a Material Definitive Agreement.
On November 5, 2015, a wholly-owned subsidiary of OPKO Health, Inc. (the "Company"),
Bio-Reference Laboratories, Inc. ("BRLI"), and certain of its subsidiaries entered into a new
credit agreement with JPMorgan Chase Bank, N.A. ("CB"), as lender and administrative agent (the
"New Credit Agreement"), which replaces BRLI's existing loan agreement with PNC Bank, National
Association (the "Existing Loan Agreement"). The New Credit Agreement provides for a $175.0
million secured revolving credit facility and includes a $20.0 million sub-facility for swingline
loans and a $20.0 million sub-facility for the issuance of letters of credit. BRLI may increase
the credit facility to up to $275.0 million on a secured basis, subject to the satisfaction of
specified conditions. The new credit facility matures on November 5, 2020 and is guaranteed by all
of BRLI's domestic subsidiaries. The new credit facility is also secured by substantially all
assets of BRLI and its domestic subsidiaries, as well as a non-recourse pledge by the Company of
its equity interest in BRLI. Availability under the New Credit Agreement is based on a borrowing
base comprised of eligible accounts receivables of BRLI and certain of its subsidiaries, as
specified therein. The proceeds of the new credit facility will be used to refinance existing
indebtedness, including amounts outstanding under the Existing Loan Agreement which has been
terminated in accordance with its terms, to finance working capital needs and for general corporate
purposes of BRLI and its subsidiaries.
At BRLI's option, borrowings under the New Credit Agreement (other than swingline loans) will
bear interest at (i) the CB floating rate (defined as the higher of (a) the prime rate and (b) the
LIBOR rate (adjusted for statutory reserve requirements for eurocurrency liabilities) for an
interest period of one month plus 2.50%) plus an applicable margin of 0.35% for the first 12 months
and 0.50% thereafter or (ii) the LIBOR rate (adjusted for statutory reserve requirements for
eurocurrency liabilities) plus an applicable margin of 1.35% for the first 12 months and 1.50%
thereafter. Swingline loans will bear interest at the CB floating rate plus the applicable margin.
The New Credit Agreement also calls for other customary fees and charges, including an unused
commitment fee of 0.25% of the lending commitments.
The New Credit Agreement contains customary covenants and restrictions, including, without
limitation, covenants that require BRLI and its subsidiaries to maintain a minimum fixed charge
coverage ratio if availability under the new credit facility falls below a specified amount and to
comply with laws, and restrictions on the ability of BRLI and its subsidiaries to incur additional
indebtedness or to pay dividends and make certain other distributions to the Company, subject to
certain exceptions as specified therein. Failure to comply with these covenants would constitute
an event of default under the New Credit Agreement, notwithstanding the ability of BRLI to meet its
debt service obligations. The New Credit Agreement also includes various customary remedies for
the lenders following an event of default, including the acceleration of repayment of outstanding
amounts under the New Credit Agreement and execution upon the collateral securing obligations under
the New Credit Agreement.
The foregoing description of the New Credit Agreement is only a summary and is qualified in
its entirety by reference to the full text of the New Credit Agreement.
Item 1.02. Termination of a Material Definitive Agreement.
The information set forth under Item 1.01 of this Current Report on Form 8-K regarding the
termination of the Existing Loan Agreement is incorporated by reference into this Item 1.02.
Item 2.03.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement of a Registrant.
The information set forth under Item 1.01 of this Current Report on Form 8-K regarding the New
Credit Agreement is incorporated by reference into this Item 2.03.
Item 7.01.
Regulation FD Disclosure.
On November 6, 2015, the Company issued a press release announcing that it entered into the
New Credit Agreement. A copy of the press release is being filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1
attached hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing by the Company under the Exchange Act.
Top of the Form
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
OPKO Health, Inc.
November 6, 2015
By:
Adam Logal
Name: Adam Logal
Title: Senior Vice President-Chief Financial Officer
Top of the Form
Exhibit Index
Exhibit No.
Description
99.1
Press Release of the Company, dated November 6, 2015